CN104151312B - 流感病毒复制抑制剂 - Google Patents

流感病毒复制抑制剂 Download PDF

Info

Publication number
CN104151312B
CN104151312B CN201410195237.XA CN201410195237A CN104151312B CN 104151312 B CN104151312 B CN 104151312B CN 201410195237 A CN201410195237 A CN 201410195237A CN 104151312 B CN104151312 B CN 104151312B
Authority
CN
China
Prior art keywords
alkyl
independently
optionally
structural formula
replacing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410195237.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104151312A (zh
Inventor
P·查理弗森
M·P·克拉克
U·K·本达拉格
R·S·贝西埃尔
J·J·库特
邓红波
I·德鲁图
J·P·杜飞
L·法莫
高淮
顾文鑫
D·H·雅各布
J·M·肯尼迪
M·W·雷德波尔
B·雷德福德
F·马尔泰斯
E·佩洛拉
王天生
M·W·瓦纳马科
U·A·格曼
S·琼斯
姜敏
林超
周毅
R·柏恩
F·G·萨利图罗
广达仪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104151312(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN104151312A publication Critical patent/CN104151312A/zh
Application granted granted Critical
Publication of CN104151312B publication Critical patent/CN104151312B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201410195237.XA 2009-06-17 2010-06-17 流感病毒复制抑制剂 Expired - Fee Related CN104151312B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18771309P 2009-06-17 2009-06-17
US61/187,713 2009-06-17
US28778109P 2009-12-18 2009-12-18
US61/287,781 2009-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080036505.3A Division CN102458408B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂

Publications (2)

Publication Number Publication Date
CN104151312A CN104151312A (zh) 2014-11-19
CN104151312B true CN104151312B (zh) 2016-06-15

Family

ID=42537408

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201410195237.XA Expired - Fee Related CN104151312B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201910673938.2A Pending CN110540538A (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201510221305.XA Expired - Fee Related CN104922128B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201510221329.5A Expired - Fee Related CN104940202B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201080036505.3A Expired - Fee Related CN102458408B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201910673938.2A Pending CN110540538A (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201510221305.XA Expired - Fee Related CN104922128B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201510221329.5A Expired - Fee Related CN104940202B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂
CN201080036505.3A Expired - Fee Related CN102458408B (zh) 2009-06-17 2010-06-17 流感病毒复制抑制剂

Country Status (37)

Country Link
US (7) US20120171245A1 (enExample)
EP (3) EP3427738B1 (enExample)
JP (6) JP5721706B2 (enExample)
KR (3) KR101903354B1 (enExample)
CN (5) CN104151312B (enExample)
AP (1) AP3631A (enExample)
AR (1) AR077130A1 (enExample)
AU (1) AU2010262905B2 (enExample)
BR (1) BRPI1011993A2 (enExample)
CA (1) CA2764177C (enExample)
CL (1) CL2011003192A1 (enExample)
CO (1) CO6491048A2 (enExample)
CY (2) CY1118246T1 (enExample)
DK (2) DK2442809T3 (enExample)
EA (3) EA025276B1 (enExample)
EC (1) ECSP12011610A (enExample)
ES (2) ES2604667T3 (enExample)
GE (5) GEP20207129B (enExample)
HR (2) HRP20161577T1 (enExample)
HU (1) HUE031048T2 (enExample)
IL (2) IL216980B (enExample)
LT (2) LT3141252T (enExample)
ME (1) ME02558B (enExample)
MX (3) MX375432B (enExample)
NZ (2) NZ619259A (enExample)
PE (2) PE20160127A1 (enExample)
PH (1) PH12015501678B1 (enExample)
PL (2) PL2442809T3 (enExample)
PT (2) PT2442809T (enExample)
RS (2) RS55341B1 (enExample)
SG (3) SG10201405827PA (enExample)
SI (2) SI2442809T1 (enExample)
TR (1) TR201815272T4 (enExample)
TW (4) TWI483941B (enExample)
UY (1) UY32717A (enExample)
WO (1) WO2010148197A1 (enExample)
ZA (2) ZA201109127B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104940202A (zh) * 2009-06-17 2015-09-30 沃泰克斯药物股份有限公司 流感病毒复制抑制剂

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354139A1 (en) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2012083121A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
MX2013006836A (es) * 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
MX2013006840A (es) * 2010-12-16 2014-01-31 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
DK2729445T3 (en) 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
ES2804528T3 (es) * 2011-07-05 2021-02-08 Vertex Pharma Procesos y productos intermedios para la producción de azaindoles
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US10323012B2 (en) * 2012-06-05 2019-06-18 Hong Kong Baptist University Miliusanes as antiviral agents
EP2858984A1 (en) * 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
RS57541B1 (sr) * 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
HUE044667T2 (hu) * 2013-11-13 2019-11-28 Vertex Pharma Influenza vírus replikáció inhibitorok
EP3068434A1 (en) * 2013-11-13 2016-09-21 Vertex Pharmaceuticals Inc. Formulations of azaindole compounds
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
AU2015240535A1 (en) 2014-04-04 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2015298876B2 (en) * 2014-08-08 2020-02-13 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
US9932346B2 (en) * 2014-09-08 2018-04-03 Janssen Sciences Ireland Uc Pyrrolopyrimidines for use in influenza virus infection
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
WO2016113277A1 (en) * 2015-01-16 2016-07-21 Bayer Cropscience Aktiengesellschaft Method for preparing 4-cyanopiperidine hydrochloride
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US20180134730A1 (en) * 2015-05-26 2018-05-17 BoroPharm Inc. Improved process for preparing boryl 7-azaindole compounds
SI3380467T1 (sl) 2015-11-27 2021-08-31 Janssen Sciences Ireland Unlimited Company Heterociklični indoli za uporabo v okužbi z virusom gripe
CN106854205B (zh) * 2015-12-09 2019-07-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CA3007758A1 (en) * 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Functionalized pentanoic acids for use in influenza viral infections
US10611755B2 (en) * 2016-01-20 2020-04-07 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
CN109071567B (zh) * 2016-05-19 2021-03-23 四川大学 抗流感小分子化合物及其制备方法和用途
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
SG11201901894TA (en) * 2016-09-05 2019-04-29 Guangdong Raynovent Biotech Co Ltd Anti-influenza virus pyrimidine derivatives
WO2018087527A1 (en) * 2016-11-08 2018-05-17 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors
WO2018108125A1 (en) 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
EP4306166A3 (en) 2016-12-23 2024-06-26 Aquinnah Pharmaceuticals Inc. Compounds, compositions and methods of use
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN110603041A (zh) 2017-04-12 2019-12-20 沃泰克斯药物股份有限公司 用于治疗流感病毒感染的组合治疗
SG11201909478UA (en) * 2017-04-24 2019-11-28 Cocrystal Pharma Inc Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
SG11202000532SA (en) 2017-08-09 2020-02-27 Denali Therapeutics Inc Compounds, compositions and methods
MA50063A (fr) 2017-09-01 2021-04-28 Denali Therapeutics Inc Composés, compositions et procédés
CN109745309B (zh) * 2017-11-03 2022-01-28 香港浸会大学 作为抗病毒剂的密瘤杀
CN110117285B (zh) * 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CA3092315C (en) * 2018-03-05 2023-08-29 Jian Xiong Crystal form and salt form of pyridopyrazole compound and preparation method therefor
WO2019193428A1 (en) 2018-04-06 2019-10-10 Janssen Pharmaceuticals, Inc. Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
WO2020023813A1 (en) * 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
MX2021001870A (es) 2018-08-17 2021-07-15 Ptc Therapeutics Inc Metodo para tratar cancer pancreatico.
PH12021551923A1 (en) 2019-02-13 2022-08-01 Denali Therapeutics Inc Compounds, compositions and methods
WO2020167994A1 (en) 2019-02-13 2020-08-20 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020181247A1 (en) * 2019-03-06 2020-09-10 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020212399A1 (en) 2019-04-15 2020-10-22 Janssen Pharmaceutica Nv Method for preparing an alkyl trans-3-aminobicyclo[2.2.2]octane-2-carboxylic acid ester compound
US20200397784A1 (en) 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds
JP7450017B2 (ja) 2019-07-22 2024-03-14 広東衆生睿創生物科技有限公司 ピリミジン誘導体の優位な塩形およびその結晶形
CA3148490C (en) * 2019-08-30 2024-04-30 Jae Won Lee Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
RU2726119C1 (ru) * 2019-11-22 2020-07-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые производные полиолов, их применение, фармацевтическая композиция на их основе
CN115698011B (zh) 2020-07-10 2023-10-20 四川海思科制药有限公司 Pb2抑制剂及其制备方法和用途
CN112979647B (zh) * 2021-03-12 2022-05-20 浙江大学 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
NZ221717A (en) 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
US6187713B1 (en) 1996-10-31 2001-02-13 Corning Incorporated Method of making activated carbon bodies having improved adsorption properties
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
WO2000040554A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
JP2003503456A (ja) 1999-07-02 2003-01-28 スチュアート エイ． リプトン 神経傷害またはアポトーシスを軽減する方法
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
NZ524192A (en) 2000-08-14 2005-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
RU2290179C2 (ru) 2000-09-06 2006-12-27 Орто-Макнейл Фармасьютикал, Инк. Способ лечения аллергий с использованием замещенных пиразолов
WO2002020013A2 (en) 2000-09-06 2002-03-14 Ortho Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
EP1322652A1 (en) 2000-09-22 2003-07-02 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
ES2290187T3 (es) 2000-12-22 2008-02-16 Wyeth Compuestos de heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6.
US20030165873A1 (en) 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
EP1392697B1 (en) 2001-03-14 2004-11-03 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino 2,3-f]quinoline
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002085896A1 (en) 2001-04-24 2002-10-31 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
DE60206048T2 (de) 2001-04-26 2006-07-13 Wyeth Antidepressive (sssri) azaheterocyclylmethylderivate von 7,8-dihydro-3h-6,9-dioxa-1,3-diazacyclopenta [a] naphthalin
BR0209342A (pt) 2001-04-26 2004-06-15 Wyeth Corp Antidepressivos de azaheterociclilmetila derivados de 2,3 dihidro-1,4-dioxino[2,3-f]quinoxalina; método de tratamento usando tais compostos; processo para prepará-los
WO2002088129A1 (en) 2001-04-26 2002-11-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
US6552049B2 (en) 2001-04-26 2003-04-22 Wyeth Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
MXPA03009829A (es) 2001-04-30 2005-03-07 Wyeth Corp Azaheterociclilmetil derivados de 7,8-dihidro-1,6,9-trioxa-3-azaciclopenta[a]naftaleno como agentes antidepresivos.
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
AU2002309769B2 (en) 2001-05-17 2008-04-17 Wyeth Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline
MXPA03011652A (es) 2001-06-15 2004-05-31 Vertex Pharma 5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa.
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AR035083A1 (es) 2001-07-25 2004-04-14 Wyeth Corp Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
WO2003015798A1 (fr) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Nouvelle methode virocide/inhibitrice de la proliferation virale et nouvel analogue de pyradine nucleotide/pyradine nucleoside
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
CA2494100C (en) 2002-08-02 2011-10-11 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2005012304A2 (en) 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EP1675830A4 (en) 2003-09-30 2008-08-20 Scios Inc HETEROCYCLIC AMIDES AND SULFONAMIDES
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
WO2005062795A2 (en) 2003-12-19 2005-07-14 Plexxikon, Inc. Compounds and methods for development of ret modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
EP1730146B1 (en) 2004-03-30 2011-05-04 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
RU2006138621A (ru) 2004-04-02 2008-05-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
WO2006009755A2 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005294575B2 (en) 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20070090172A (ko) 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘
AU2005309566A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
LT2377557T (lt) 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
JP4954086B2 (ja) 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー １ｈ−ピロロ［２，３−ｂ］ピリジン
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8633205B2 (en) 2005-02-03 2014-01-21 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases
CA2608333A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
EP2354139A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
CA2623032A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
AU2007207533B8 (en) 2006-01-17 2012-06-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of Janus kinases
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
EP2004645A2 (en) 2006-02-14 2008-12-24 Vertex Pharmaceuticals, Inc. Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
EP2001884A1 (en) 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Deazapurines useful as inhibitors of janus kinases
US8252792B2 (en) * 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20090017444A1 (en) 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
NZ575274A (en) 2006-08-08 2010-11-26 Chugai Pharmaceutical Co Ltd Pyrimidine derivative as pi3k inhibitor and use thereof
EP2057140B1 (en) * 2006-08-24 2012-08-08 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
ES2359467T3 (es) 2006-12-14 2011-05-23 Vertex Pharmceuticals Incorporated Compuestos útiles como inhibidores de proteína quinasas.
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
EP2137183B1 (en) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
ES2435997T3 (es) 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
WO2008113711A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
UA98324C2 (ru) 2007-04-05 2012-05-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
NZ583061A (en) 2007-08-15 2012-06-29 Vertex Pharma 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
WO2009040556A1 (en) 2007-09-28 2009-04-02 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
CN101970465B (zh) 2007-10-09 2016-03-16 欧洲分子生物学实验室(Embl) 能够结合rna帽的流感病毒pb2蛋白可溶性片段
JP5444239B2 (ja) 2007-11-02 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
PT2247592E (pt) 2008-02-25 2011-11-03 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
EP2297200A1 (en) 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
JP5634990B2 (ja) 2008-06-23 2014-12-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質キナーゼ阻害剤
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000839A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
MX2011000837A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa triciclica.
WO2010011762A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
CN104151312B (zh) * 2009-06-17 2016-06-15 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
JP2012533553A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
CA2796388A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2563125A4 (en) 2010-04-27 2013-10-02 Merck Sharp & Dohme AZAINDOLE AS JANUSKINASE HEMMER
MX2013006840A (es) 2010-12-16 2014-01-31 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
WO2012083121A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
ES2804528T3 (es) 2011-07-05 2021-02-08 Vertex Pharma Procesos y productos intermedios para la producción de azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2776036A1 (en) 2011-11-07 2014-09-17 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
MX2016002176A (es) 2013-08-22 2016-06-23 Vertex Pharma Azaindoles enriquecidos isotopicamente.
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
EP3068434A1 (en) 2013-11-13 2016-09-21 Vertex Pharmaceuticals Inc. Formulations of azaindole compounds
HUE044667T2 (hu) 2013-11-13 2019-11-28 Vertex Pharma Influenza vírus replikáció inhibitorok
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
AU2015298876B2 (en) 2014-08-08 2020-02-13 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
US9932346B2 (en) 2014-09-08 2018-04-03 Janssen Sciences Ireland Uc Pyrrolopyrimidines for use in influenza virus infection
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
SI3380467T1 (sl) 2015-11-27 2021-08-31 Janssen Sciences Ireland Unlimited Company Heterociklični indoli za uporabo v okužbi z virusom gripe
CA3007758A1 (en) 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Functionalized pentanoic acids for use in influenza viral infections
US10611755B2 (en) 2016-01-20 2020-04-07 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
CN110603041A (zh) 2017-04-12 2019-12-20 沃泰克斯药物股份有限公司 用于治疗流感病毒感染的组合治疗

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104940202A (zh) * 2009-06-17 2015-09-30 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN104940202B (zh) * 2009-06-17 2018-10-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN110540538A (zh) * 2009-06-17 2019-12-06 沃泰克斯药物股份有限公司 流感病毒复制抑制剂

Also Published As

Publication number Publication date
JP2018002747A (ja) 2018-01-11
SI2442809T1 (sl) 2017-01-31
PT3141252T (pt) 2018-11-14
GEP20227397B (en) 2022-07-25
PL2442809T3 (pl) 2017-02-28
ES2692396T3 (es) 2018-12-03
US20190151314A1 (en) 2019-05-23
US10874673B2 (en) 2020-12-29
TW201520211A (zh) 2015-06-01
GEP20156325B (en) 2015-07-10
WO2010148197A1 (en) 2010-12-23
US9518056B2 (en) 2016-12-13
AP2012006067A0 (en) 2012-02-29
LT3141252T (lt) 2018-11-12
US20140142119A1 (en) 2014-05-22
GEAP202213376A (en) 2022-02-25
US10039762B2 (en) 2018-08-07
CA2764177A1 (en) 2010-12-23
ZA201500820B (en) 2016-05-25
TWI574963B (zh) 2017-03-21
TW201925196A (zh) 2019-07-01
JP2015038146A (ja) 2015-02-26
SG176722A1 (en) 2012-01-30
EP2442809B1 (en) 2016-08-31
US9345708B2 (en) 2016-05-24
NZ597059A (en) 2014-01-31
PE20160127A1 (es) 2016-02-24
HRP20181715T1 (hr) 2019-04-05
CL2011003192A1 (es) 2013-01-04
EP3141252B1 (en) 2018-07-25
EP3427738A1 (en) 2019-01-16
CN104922128A (zh) 2015-09-23
US20180078553A1 (en) 2018-03-22
AP3631A (en) 2016-03-08
TW201103935A (en) 2011-02-01
JP2016204390A (ja) 2016-12-08
CN102458408A (zh) 2012-05-16
CO6491048A2 (es) 2012-07-31
MX348066B (es) 2017-05-26
IL262734B (en) 2020-11-30
JP2020011990A (ja) 2020-01-23
JP6348939B2 (ja) 2018-06-27
SI3141252T1 (sl) 2018-12-31
US20170100400A1 (en) 2017-04-13
KR20180108856A (ko) 2018-10-04
EA201500266A1 (ru) 2015-10-30
HRP20161577T1 (hr) 2017-01-27
EA037529B1 (ru) 2021-04-08
EP3427738B1 (en) 2021-12-01
MX2011013475A (es) 2012-03-14
CY1118246T1 (el) 2017-06-28
PT2442809T (pt) 2016-12-06
EA030188B1 (ru) 2018-07-31
AU2010262905A1 (en) 2012-01-12
IL216980B (en) 2018-11-29
ME02558B (me) 2017-02-20
HK1215530A1 (zh) 2016-09-02
US20160152614A1 (en) 2016-06-02
AU2010262905B2 (en) 2015-04-16
HK1215675A1 (zh) 2016-09-09
LT2442809T (lt) 2016-12-12
TWI483941B (zh) 2015-05-11
JP2015034177A (ja) 2015-02-19
AR077130A1 (es) 2011-08-03
EA025276B1 (ru) 2016-12-30
EA201500871A8 (ru) 2019-02-28
KR102050712B1 (ko) 2019-12-02
KR101903354B1 (ko) 2018-10-04
CN102458408B (zh) 2015-06-03
DK3141252T3 (en) 2018-11-19
ES2604667T3 (es) 2017-03-08
JP2012530713A (ja) 2012-12-06
PH12015501678B1 (en) 2022-07-06
IL262734A (en) 2018-12-31
EA201500871A1 (ru) 2016-11-30
HK1169326A1 (en) 2013-01-25
DK2442809T3 (en) 2016-12-19
EP2442809A1 (en) 2012-04-25
ZA201109127B (en) 2015-07-29
PL3141252T3 (pl) 2019-01-31
SG10201405826RA (en) 2014-12-30
EP3141252A1 (en) 2017-03-15
US8829007B2 (en) 2014-09-09
RS55341B1 (sr) 2017-03-31
SG10201405827PA (en) 2014-11-27
EP3141252B8 (en) 2019-03-13
JP6620135B2 (ja) 2019-12-11
KR101702609B1 (ko) 2017-02-03
JP6030619B2 (ja) 2016-11-24
GEP20207129B (en) 2020-07-10
NZ619259A (en) 2015-07-31
PH12015501678A1 (en) 2020-06-22
UY32717A (es) 2011-01-31
CA2764177C (en) 2018-06-05
CY1120778T1 (el) 2019-12-11
PE20120508A1 (es) 2012-05-09
HUE031048T2 (en) 2017-06-28
RS57869B1 (sr) 2018-12-31
TWI639596B (zh) 2018-11-01
US20140296201A1 (en) 2014-10-02
TW201728584A (zh) 2017-08-16
CN104940202A (zh) 2015-09-30
KR20170015551A (ko) 2017-02-08
CN110540538A (zh) 2019-12-06
JP5721706B2 (ja) 2015-05-20
MX375432B (es) 2025-03-06
IL216980A0 (en) 2012-02-29
ECSP12011610A (es) 2012-02-29
CN104922128B (zh) 2019-12-20
EA201270032A1 (ru) 2012-07-30
BRPI1011993A2 (pt) 2021-07-06
HK1204322A1 (en) 2015-11-13
US20120171245A1 (en) 2012-07-05
US9808459B2 (en) 2017-11-07
KR20120097471A (ko) 2012-09-04
TWI666209B (zh) 2019-07-21
CN104940202B (zh) 2018-10-16
TR201815272T4 (tr) 2018-11-21
GEAP202013375A (en) 2020-02-10
CN104151312A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
CN104151312B (zh) 流感病毒复制抑制剂
CN105503862B (zh) 流感病毒复制抑制剂
CN103492381A (zh) 流感病毒复制的抑制剂
HK40020057A (en) Inhibitors of influenza viruses replication
AU2018200219B2 (en) Inhibitors of Influenza Viruses Replication
HK1204322B (en) Inhibitors of influenza viruses replication
HK1169326B (en) Inhibitors of influenza viruses replication
HK1215530B (zh) 流感病毒复制抑制剂
HK1215675B (zh) 流感病毒复制抑制剂
HK1194736B (en) Inhibitors of influenza viruses replication
HK1223914B (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204322

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1204322

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160615

CF01 Termination of patent right due to non-payment of annual fee